Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Milan Summit On Precision Medicine /
Clinical validity of NGS and innovation in clinical diagnosis

8th - 9th Feb 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 21.02.18
Views: 3786

Dr Jeffrey Ross - Albany Medical College, Albany, USA

Dr Jeffrey Ross presents at ecancer's Milan Summit on Precision Medicine 2018 about the uses and limitations of NGS in precision medicine.

He highlights important limiting factors and examples of mutations which require highly sensitive technology.

He also goes in to detail regarding the FoundationOne assay.

Overall, Dr Ross encourages the marrying of clinical and genomic data to drive discovery in cancer research.

The webcast has been supported by an unrestricted educational grant from Roche Foundation Medicine

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation